Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes: Adiponectin in type 1 diabetes
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Forsblom C, Thomas MC, Moran J, Saraheimo M, Thorn L, Wadén J, Gordin D, Frystyk J, Flyvbjerg A, Groop P-H, on behalf of the FinnDiane Study Group (Folkhälsan Institute of Genetics, Helsinki; Department of Medicine Helsinki University Central Hospital, Helsinki, Finland; The Baker IDI Heart and Diabetes Institute, Melbourne, Vic.; The Queen Elizabeth Hospital, Woodville, SA, Australia; and Aarhus University Hospital, Aarhus C., Denmark). Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med 2011; 270: 346–355. Background. Adiponectin is widely regarded as an anti-atherogenic, antioxidant and anti-inflammatory molecule. However, adiponectin concentration is paradoxically increased in individuals with type 1 diabetes, in whom it is positively associated with adverse clinical outcomes. Objective. To explore the association between serum adiponectin concentration and mortality outcomes in adults with type 1 diabetes. Design. Multicentre prospective cohort study. Setting. Primary and tertiary care. Subjects. Finnish adults with type 1 diabetes (n = 2034). Main outcome measures. All-cause and cardiovascular mortality. Independent predictors of mortality were determined using the Cox and the Fine and Gray competing risks proportional hazards models. Results. During a median of 11 years of follow-up, there were 173 deaths (8.5%, 1.0 per hundred person-years). Adiponectin was linearly associated with all-cause mortality [Cox model: hazard ratio (HR) 1.02, 95% confidence interval (CI) 1.01–1.03, P < 0.001] and cardiovascular mortality (Fine and Gray model: HR 1.02, 95% CI 1.00–1.04, P = 0.035); patients with the highest adiponectin concentrations had the shortest survival. The mortality risk associated with adiponectin was independent of glycaemic and lipid control, pre-existing cardiovascular disease, markers of inflammation and the presence and severity of kidney disease. Conclusions. Although adiponectin is generally considered to be a protective molecule, increased concentrations of adiponectin in type 1 diabetes are independently associated with all-cause and cardiovascular mortality. Moreover, the fact that this association was observed for the first time in patients with normal urinary albumin levels, who have few comorbidities, suggests that adiponectin is specifically linked with vascular damage in type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome
Kadowaki, T. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29126 · Cited by 2,824
Global guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Barr, E. L. M., Zimmet, P. Z., Welborn, T. A., Jolley, D., Magliano, D. J., Dunstan, D. W., Cameron, A. J., Dwyer, T., Taylor, H. R., Tonkin, A. M., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685628 · Cited by 719
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
Self-citationPlasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure
Kistorp, C., Faber, J., Galatius, S., Gustafsson, F., Frystyk, J., Flyvbjerg, A., & Hildebrandt, P. (2005) · Circulation · doi:10.1161/circulationaha.104.530972 · Cited by 605
Self-citationDiabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients
Saraheimo, M., Teppo, A.-M., Forsblom, C., Fagerudd, J., & Groop, P.-H. (2003) · Diabetologia · doi:10.1007/s00125-003-1194-5 · Cited by 255
Self-citation
Cited by
Obesity in autoimmune diseases: Not a passive bystander
Versini, M., Jeandel, P.-Y., Rosenthal, E., & Shoenfeld, Y. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.07.001 · Cited by 694
Blüher, M., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.016 · Cited by 399
Abbenhardt, C., McTiernan, A., Alfano, C. M., Wener, M. H., Campbell, K. L., Duggan, C., Foster‐Schubert, K. E., Kong, A., Toriola, A. T., Potter, J. D., et al. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12062 · Cited by 137
Adipokines and Aging: Findings From Centenarians and the Very Old
Arai, Y., Kamide, K., & Hirose, N. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00142 · Cited by 71
Menzaghi, C., Xu, M., Salvemini, L., De Bonis, C., Palladino, G., Huang, T., Copetti, M., Zheng, Y., Li, Y., Fini, G., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0130-y · Cited by 40
Metadata
- Authors
- Forsblom, C., Thomas, M. C., Moran, J., Saraheimo, M., Thorn, L., Wadén, J., Gordin, D., Frystyk, J., Flyvbjerg, A., Groop, P.-H., & on behalf of the FinnDiane Study Group
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2011-06-23
- Volume
- 270
- Issue
- 4
- Pages
- 346-355
- ISSN
- 0954-6820 (ISSN-L)
- OpenAlex
- W1566060081
- Cited by
- 69
- References
- 6
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes: Adiponectin in type 1 diabetes. https://app.cochat.ai/papers/10.1111/j.1365-2796.2011.02406.x
- The paper
- Forsblom, C., Thomas, M. C., Moran, J., Saraheimo, M., Thorn, L., Wadén, J., Gordin, D., Frystyk, J., Flyvbjerg, A., Groop, P.-H., & on behalf of the FinnDiane Study Group. (2011). Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes: Adiponectin in type 1 diabetes. Journal of Internal Medicine. https://doi.org/10.1111/j.1365-2796.2011.02406.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.